What is the 13F Pro Quality Score for CTKB?

13F Pro ranks Cytek Biosciences, Inc. (CTKB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CTKB's current score at https://13fpro.ai/research/CTKB (free sign-up required for the full ranking).

Where does 13F Pro source CTKB data?

All Cytek Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cytek Biosciences, Inc. files with the SEC under CIK 1831915. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CTKB in?

Cytek Biosciences, Inc. (CTKB) is classified in the Technology sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/technology.

How often is CTKB research updated on 13F Pro?

CTKB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cytek Biosciences, Inc.(CTKB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Technology →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1831915 CTKB stock profile & AI dashboard →

13F Pro Quality Score

25.8/100

Rank #2,533 of 2,879 stocks

View Technology peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

36.0/100

Profitability

14.0/100

Balance Sheet

18.8/100

Earnings Quality

30.0/100

Free Cash Flow

22.2/100

Institutional Flow

78.1/100

Revenue Scale

23.3/100

Dilution Risk

14.8/100

CTKB Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cytek Biosciences, Inc. (CTKB), a Technology sector company. 13F Pro's AI-powered ranking engine scores CTKB at 25.8/100 on a 32-signal composite quality model, placing it at rank #2,533 of 2,879 stocks — the bottom half of the AI-ranked universe. CTKB scores in the top quartile across institutional flow (78.1). Areas of concern include profitability (14.0) and balance sheet strength (18.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Cytek Biosciences, Inc. reports quarterly revenue of $44.1M, net income of $-18.9M, free cash flow of $-4.9M. Top institutional holders of CTKB by reported 13-F value include BlackRock,, Topline Capital Management,, Hillhouse Capital Advisors, Ltd., based on the most recent SEC filings. CTKB trades on the Nasdaq exchange and files with the SEC under CIK 1831915. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CTKB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cytek Biosciences, Inc. directly from SEC EDGAR. Cytek Biosciences, Inc.'s 13F Pro composite quality score has ranged between 8 and 53 since 2022, currently 25.8 — a declining long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about Cytek Biosciences, Inc.

Quirks, history, and lore behind CTKB — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. life sciences technology company · listed on Nasdaq · headquartered in California · serves the biomedical research market.
2
The Numbers
A small-cap company with annual revenue in the range of $100–200 million — not a household name, but its instruments sit in some very serious labs.
3
The History
Founded in the 2010s, it grew out of cutting-edge academic research and went public around 2021, riding the biotech instrumentation wave.
4
The Secret
Its core technology pushes flow cytometry far beyond the conventional limit — where most systems measure a handful of parameters, this one can measure dozens simultaneously.
5
The Lore
Its flagship platform is called Aurora — fitting, since it reveals a dazzling spectrum of cellular detail that older instruments simply couldn't see.
6
The Giveaway
When researchers need full-spectrum flow cytometry with up to 40+ parameters per cell, they turn to this Fremont, CA company whose ticker starts with the letters of its initials.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$44.1M

Net Income

Q1 2026

$-18.9M

Free Cash Flow

Q1 2026

$-4.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+6665.2% YoY

$200.5MFY 2024

FY21 $2.2MFY22 $3.0MFY24 $200.5M

Net Income

-342.4% YoY

$-6.0MFY 2024

FY21 $3.0MFY22 $2.5MFY24 $-6.0M

Operating Income

-1037.6% YoY

$-20.5MFY 2024

FY21 $9.2MFY22 $-1.8MFY24 $-20.5M

EPS (Diluted)

—FY 2024

FY21 $0.00FY22 $0.02FY24 —

Total Assets

-3.8% YoY

$499.5MFY 2024

FY21 $463.3MFY22 $519.5MFY24 $499.5M

Op. Cash Flow

+307.5% YoY

$25.4MFY 2024

FY21 $4.6MFY22 $-12.2MFY24 $25.4M

Metric	FY 2024	FY 2022	FY 2021
Revenue	$200.5M +6665.2%	$3.0M +35.9%	$2.2M
Net Income	$-6.0M -342.4%	$2.5M -17.9%	$3.0M
Operating Income	$-20.5M -1037.6%	$-1.8M -119.7%	$9.2M
EPS (Diluted)	—	$0.02	$0.00
Total Assets	$499.5M -3.8%	$519.5M +12.1%	$463.3M
Operating Cash Flow	$25.4M +307.5%	$-12.2M -364.2%	$4.6M

AI Insight: CTKB Financial Trends

Q1 2026 operating loss deepened to -$18M — the worst in eight quarters — while equity has eroded $61M since Q4 2024.

• Revenue shows seasonality but no net growth: Q1 2026 at $44M is roughly flat versus Q1 2025 at $41M, with peak quarters capped around $62M.

• Operating income deteriorated from a brief $3M profit in Q4 2024 back to -$18M in Q1 2026, erasing the only profitable quarter in the dataset.

• Operating cash flow turned persistently negative from Q1 2025 onward, swinging from +$13M in Q3 2024 to -$3M in Q1 2026.

• Equity has declined from $396M in Q4 2024 to $328M in Q1 2026, a $68M contraction over five quarters.

⚠ Net loss widened to -$19M in Q1 2026 versus -$11M in Q1 2025 — deteriorating year-over-year on the same seasonal trough quarter.

⚠ Sustained negative operating cash flow since Q1 2025 raises questions about cash runway given no debt data is available to assess liquidity buffer.

⚠ Whether Q4 seasonality can again deliver positive operating income — the only such quarter — will signal if the model has a viable profitability path.

AI Insight: CTKB Ratio Trends

Q1 2026 operating margin collapsed to -41.8%, the worst reading in the dataset, reversing a sequential recovery trend that had lifted margins to +5.2% in Q4 2024.

• Operating margin deteriorated sharply from -9.0% in Q4 2025 to -41.8% in Q1 2026, erasing four quarters of sequential improvement.

• ROIC plunged from -6.6% in Q4 2025 to -22.5% in Q1 2026, the worst ROIC reading across all periods shown.

• Net profit margin fell from -27.5% in Q1 2025 to -42.8% in Q1 2026, a year-over-year deterioration of 15.3 percentage points.

⚠ Q1 seasonality appears severe: Q1 2025 also saw the worst OpMargin of that year at -36.1%. Monitor whether Q2 2026 recovers similarly.

⚠ ROE worsened from -12.0% in Q1 2025 to -23.0% in Q1 2026, signaling accelerating equity erosion if losses persist.

⚠ D/E data is absent across all periods; leverage visibility is limited and warrants scrutiny in upcoming disclosures.

Get alerted when CTKB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cytek Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CTKB

BlackRock, Inc.
$74.3M17,007,269 sh
Topline Capital Management, LLC
$30.9M7,064,481 sh
Hillhouse Capital Advisors, Ltd.
$29.1M6,657,030 sh
MILLENNIUM MANAGEMENT LLC
$27.5M6,291,798 sh
Boston Partners
$25.4M5,802,773 sh
VANGUARD CAPITAL MANAGEMENT LLC
$20.8M4,762,904 sh
STATE STREET CORP
$18.0M4,123,748 sh
GEODE CAPITAL MANAGEMENT, LLC
$12.4M2,833,955 sh
DIMENSIONAL FUND ADVISORS LP
$11.6M2,663,329 sh
GOLDMAN SACHS GROUP INC
$10.2M2,344,735 sh

Fund	Value	Shares
BlackRock, Inc.	$74.3M	17,007,269
Topline Capital Management, LLC	$30.9M	7,064,481
Hillhouse Capital Advisors, Ltd.	$29.1M	6,657,030
MILLENNIUM MANAGEMENT LLC	$27.5M	6,291,798
Boston Partners	$25.4M	5,802,773
VANGUARD CAPITAL MANAGEMENT LLC	$20.8M	4,762,904
STATE STREET CORP	$18.0M	4,123,748
GEODE CAPITAL MANAGEMENT, LLC	$12.4M	2,833,955
DIMENSIONAL FUND ADVISORS LP	$11.6M	2,663,329
GOLDMAN SACHS GROUP INC	$10.2M	2,344,735

More Technology Companies

View all Technology →

AGILENT TECHNOLOGIES, INC.

AAOI

APPLIED OPTOELECTRONICS, INC.

AAPL

Apple Inc.

ABNB

Airbnb, Inc.

ACCL

Acco Group Holdings Ltd

ACCS

ACCESS Newswire Inc.

ACFN

ACORN ENERGY, INC.

ACIW

ACI WORLDWIDE, INC.

Put CTKB on your watchlist

Track score changes the day Cytek Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CTKB a good stock to buy?

13F Pro's AI-powered analysis of Cytek Biosciences, Inc. (CTKB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CTKB are available on the CTKB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CTKB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CTKB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cytek Biosciences, Inc.'s investment landscape.